NasdaqCM - Nasdaq Real Time Price USD

Bio-Path Holdings, Inc. (BPTH)

2.6599 -0.0251 (-0.94%)
As of 11:20 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Peter H. Nielsen MBA Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer 696.24k -- 1949
Mr. Douglas P. Morris Co-Founder, Director of Investor Relations, Secretary & Director 73.74k -- 1956
Mr. Michael Hickey M.B.A. VP of Clinical Operations -- -- --
Mr. Anthony Price Senior Vice President of Finance, Accounting & Administration -- -- --
Dr. Ana Tari Ashizawa Ph.D., MBA Senior Vice President of Research, Development & Clinical Design -- -- --

Bio-Path Holdings, Inc.

4710 Bellaire Boulevard
Suite 210
Bellaire, TX 77401
United States
832 742 1357 https://www.biopathholdings.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
10

Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Corporate Governance

Bio-Path Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 10, 2024 - May 14, 2024
Bio-Path Holdings, Inc. Earnings Call

Related Tickers

MLEC Moolec Science SA
1.4715
-14.95%
 
PALI Palisade Bio, Inc.
5.83
-1.53%
 
NKGN NKGen Biotech, Inc.
1.8985
+2.63%
 
VNDA Vanda Pharmaceuticals Inc.
4.5900
-0.86%
 
JAGX Jaguar Health, Inc.
0.1706
+1.55%
 
BNTC Benitec Biopharma Inc.
7.13
+3.99%
 
IBRX ImmunityBio, Inc.
5.20
-5.37%
 
LGVN Longeveron Inc.
1.7200
-5.49%
 
CLNN Clene Inc.
0.3311
-1.21%
 
CTXR Citius Pharmaceuticals, Inc.
0.7280
-5.11%